Week In Review: InnoCare Prices Hong Kong IPO To Raise $288 Million

InnoCare Pharma of Beijing priced its Hong Kong IPO at the top end of its proposed range to raise $288 million at a $1 billion valuation, according to insiders. The company develops immunotherapies for cancer and autoimmune diseases.